These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1056 related articles for article (PubMed ID: 29713086)

  • 1. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM
    Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
    Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
    J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
    González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
    Breast Cancer Res Treat; 2016 Apr; 156(3):507-515. PubMed ID: 27083178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
    Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
    Zhang L; Wu Z; Li J; Zhu D; Yang L; Shao Y; Lin Y; Liu Z; Cao Y; Zhang G; Shang S; Zhang Y; Wang K
    JCO Precis Oncol; 2023 Jan; 7():e2200337. PubMed ID: 36652665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
    Telli ML; Jensen KC; Vinayak S; Kurian AW; Lipson JA; Flaherty PJ; Timms K; Abkevich V; Schackmann EA; Wapnir IL; Carlson RW; Chang PJ; Sparano JA; Head B; Goldstein LJ; Haley B; Dakhil SR; Reid JE; Hartman AR; Manola J; Ford JM
    J Clin Oncol; 2015 Jun; 33(17):1895-901. PubMed ID: 25847929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
    JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do platinum salts fit all triple negative breast cancers?
    Gerratana L; Fanotto V; Pelizzari G; Agostinetto E; Puglisi F
    Cancer Treat Rev; 2016 Jul; 48():34-41. PubMed ID: 27343437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
    Tovey H; Sipos O; Parker JS; Hoadley KA; Quist J; Kernaghan S; Kilburn L; Salgado R; Loi S; Kennedy RD; Roxanis I; Gazinska P; Pinder SE; Bliss J; Perou CM; Haider S; Grigoriadis A; Tutt A; Cheang MCU
    Clin Cancer Res; 2023 Sep; 29(18):3691-3705. PubMed ID: 37574209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 12p Amplification in Triple-Negative/
    Gómez-Miragaya J; Díaz-Navarro A; Tonda R; Beltran S; Palomero L; Palafox M; Dobrolecki LE; Huang C; Vasaikar S; Zhang B; Wulf GM; Collado-Sole A; Trinidad EM; Muñoz P; Paré L; Prat A; Bruna A; Caldas C; Arribas J; Soler-Monso MT; Petit A; Balmaña J; Cruz C; Serra V; Pujana MA; Lewis MT; Puente XS; González-Suárez E
    Cancer Res; 2019 Aug; 79(16):4258-4270. PubMed ID: 31213465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.